TY - JOUR T1 - Response to statin therapy in obstructive sleep apnea (OSA): A randomized controlled trial JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - 5032 AU - Renaud Tamisier AU - Jean-Philippe Baguet AU - Marie Joyeux-Faure AU - Sonia Dias-Domingos AU - Stephen Perrig AU - Georges Leftheriotis AU - Jean-Paul Janssens AU - Patrick Levy AU - Frédéric Gagnadoux AU - Jean-Louis Pepin Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/5032.abstract N2 - Rationale: Accumulated evidence implicates oxidative stress and vascular inflammation in favoring sympathetic activation, hypertension, endothelial dysfunction and atherosclerosis in OSA. Statins through pleiotropic properties might modify cardiovascular outcomes in OSA. This study aimed to compare the effects of atorvastatin with placebo on endothelial function. Methods: This multicenter, randomized, double-blind, parallel group study compared atorvastatin 40mg and placebo over 12 weeks. The primary endpoint was endothelial function change from baseline at 12 weeks measured by peripheral arterial tone (PAT). Other endpoints included office blood pressure (BP), carotid early atherosclerosis (intima media thickness (IMT) and carotid diameters), arterial stiffness measured by pulse wave velocity (PWV) and metabolic parameters. Primary analysis was intention to treat. Results: 51 severe OSA (apnea+hypopnea index (AHI): 44.4±16.2/h) were randomized. Key demographics for the study population included: mean age 54±11 years, 21.6% female, mean BMI 28.5±4.5 kg/m2. At endpoint, mean difference in endothelial function (PAT) between atorvastatin and placebo groups was 0.008 (-0.29 ; 0.28) (p=0.98). Total and LDL cholesterols significantly improved with atorvastatin (p<0.001). Systolic BP significantly decreased with atorvastatin (mean difference: -6.34 mmHg (-12.68 ; -0.01), p=0.05) whereas carotid IMT, diameters and PWV were unchanged compared to the placebo group. Conclusion: In OSA patients, 3 months of atorvastatin neither improved endothelial function nor reduced early signs of atherosclerosis although it lowered blood pressure and improved lipid profile. Trial registration: NCT00669695. ER -